|Cell Line Name:||NCI-H69/LX10|
|Keywords:||Human small cell lung cancer, drug-resistant|
|Cell Line Description:||The drug-resistant cell line NCI-H69/LX10 has been derived from the parent line NCI-H69 (ECACC No 91091802). It is recommended to culture the cells without drug upon resuscitation; add doxorubicine once growth is fully established.|
|Growth Mode:||Aggregates in suspension|
|Subculture Routine:||Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2, 37ºC; resuscitate in drug-free medium and add drug after growth has been established.|
|Culture Medium:||RPMI 1640 + 2mM Glutamine + 1.0 µg/ml doxorubicine + 10% Foetal Bovine Serum (FBS).|
|Depositor:||Dr P Twentyman, Dr. K. Wright, UKCCR, PO Box 123, Lincolns Inn Fields, London WC2A 3PX|
|References:||None specified by depositor|
|Additional Bibliography:||Not specified|
|Patents:||None specified by Depositor|
|Research Council Deposit:||Yes|
The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.
Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.